Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size.
Cognitive function
late effects
outcomes
proton radiation therapy
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
03
05
2022
received:
04
11
2021
accepted:
04
05
2022
pubmed:
17
6
2022
medline:
27
7
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
The Neurological Predictor Scale (NPS) quantifies cumulative exposure to conventional treatment-related neurological risks but does not capture potential risks posed by tumors themselves. This study evaluated the predictive validity of the NPS, and the incremental value of tumor location and size, for neurocognitive outcomes in early survivorship following contemporary therapies for pediatric brain tumors. Survivors (N = 69) diagnosed from 2010 to 2016 were administered age-appropriate versions of the Wechsler Intelligence Scales. Hierarchical multiple regressions examined the predictive and incremental validity of NPS score, tumor location, and tumor size. Participants (51% female) aged 6-20 years (M = 13.22, SD = 4.09) completed neurocognitive evaluations 5.16 years (SD = 1.29) postdiagnosis. The NPS significantly predicted Full-Scale Intelligence Quotient (FSIQ; ΔR Tumor size emerged as an independent predictor of neurocognitive functioning and added incrementally to the predictive utility of the NPS. Pretreatment disease burden may provide one of the earliest markers of neurocognitive risk following contemporary treatments. With perpetual treatment advances, measures quantifying treatment-related risk may need to be updated and revalidated to maintain their clinical utility.
Sections du résumé
BACKGROUND
The Neurological Predictor Scale (NPS) quantifies cumulative exposure to conventional treatment-related neurological risks but does not capture potential risks posed by tumors themselves. This study evaluated the predictive validity of the NPS, and the incremental value of tumor location and size, for neurocognitive outcomes in early survivorship following contemporary therapies for pediatric brain tumors.
PROCEDURE
Survivors (N = 69) diagnosed from 2010 to 2016 were administered age-appropriate versions of the Wechsler Intelligence Scales. Hierarchical multiple regressions examined the predictive and incremental validity of NPS score, tumor location, and tumor size.
RESULTS
Participants (51% female) aged 6-20 years (M = 13.22, SD = 4.09) completed neurocognitive evaluations 5.16 years (SD = 1.29) postdiagnosis. The NPS significantly predicted Full-Scale Intelligence Quotient (FSIQ; ΔR
CONCLUSIONS
Tumor size emerged as an independent predictor of neurocognitive functioning and added incrementally to the predictive utility of the NPS. Pretreatment disease burden may provide one of the earliest markers of neurocognitive risk following contemporary treatments. With perpetual treatment advances, measures quantifying treatment-related risk may need to be updated and revalidated to maintain their clinical utility.
Identifiants
pubmed: 35709014
doi: 10.1002/pbc.29803
pmc: PMC10265925
mid: NIHMS1899482
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29803Subventions
Organisme : NCI NIH HHS
ID : R01 CA187202
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA221197
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Clin Neuropsychol. 2011 Aug;25(6):942-62
pubmed: 21722062
Child Neuropsychol. 2009 Jan;15(1):40-52
pubmed: 18608223
J Clin Oncol. 2001 Jan 15;19(2):472-9
pubmed: 11208841
Lancet Oncol. 2016 Mar;17(3):287-298
pubmed: 26830377
J Neurooncol. 2016 Mar;127(1):137-44
pubmed: 26725098
J Neurooncol. 2019 Mar;142(1):193-201
pubmed: 30607706
J Clin Oncol. 2013 Oct 1;31(28):3494-500
pubmed: 23980078
Ann Neurol. 1999 Dec;46(6):834-41
pubmed: 10589535
Neuro Oncol. 2017 Nov 29;19(12):1673-1682
pubmed: 29016818
Lancet Oncol. 2004 Jul;5(7):399-408
pubmed: 15231246
Pediatr Neurol. 2014 Oct;51(4):515-21
pubmed: 25266614
Neuro Oncol. 2019 Jun 10;21(6):809-818
pubmed: 30753584
J Clin Oncol. 2016 Apr 1;34(10):1043-9
pubmed: 26811522
Cerebellum. 2020 Feb;19(1):78-88
pubmed: 31832994
Psychooncology. 2015 Jul;24(7):804-11
pubmed: 25111013
J Int Neuropsychol Soc. 2021 Jan;27(1):1-11
pubmed: 32641194
J Clin Oncol. 2018 Sep 20;36(27):2762-2769
pubmed: 30091946
J Clin Oncol. 2020 Feb 10;38(5):454-461
pubmed: 31774710
Eur J Paediatr Neurol. 2010 Mar;14(2):106-15
pubmed: 19931477
Neuro Oncol. 2005 Jan;7(1):12-9
pubmed: 15701278
J Int Neuropsychol Soc. 2004 Mar;10(2):180-9
pubmed: 15012838
J Child Neurol. 2009 Nov;24(11):1455-63
pubmed: 19841433
Dev Neuropsychol. 2008;33(4):505-20
pubmed: 18568901
Pediatr Blood Cancer. 2010 Sep;55(3):525-31
pubmed: 20658625
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):400-7
pubmed: 26254679
J Clin Oncol. 2004 Mar 15;22(6):999-1006
pubmed: 15020603
Pediatr Blood Cancer. 2015 Oct;62(10):1805-12
pubmed: 26053691
Neuro Oncol. 2011 May;13(5):517-24
pubmed: 21372071
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
pubmed: 23095881
Neuro Oncol. 2010 Dec;12(12):1311-7
pubmed: 20713408
Pediatr Blood Cancer. 2017 Jan;64(1):172-179
pubmed: 27566994
J Child Neurol. 2008 Apr;23(4):455-8
pubmed: 18182641
Radiother Oncol. 2017 Jul;124(1):89-97
pubmed: 28655455
J Neurooncol. 2005 May;72(3):245-53
pubmed: 15937648
Child Neuropsychol. 2016;22(6):748-60
pubmed: 26069903
J Int Neuropsychol Soc. 2016 May;22(5):501-11
pubmed: 26954713
J Natl Cancer Inst. 2011 May 4;103(9):714-36
pubmed: 21454908